Please login to the form below

Not currently logged in
Email:
Password:

Inrebic

This page shows the latest Inrebic news and features for those working in and with pharma, biotech and healthcare.

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

It also comes on the heels of  another significant approval of Celgene’s JAK inhibitor Inrebic (fedratinib), which scored an FDA nod in August. ... Some analysts have predicted that Inrebic could also become a $1bn product in myelofibrosis, despite a

Latest news

  • Roche agrees $1.4bn takeover of fibrosis specialist Promedior Roche agrees $1.4bn takeover of fibrosis specialist Promedior

    anaemia. The only marketed therapies for myelofibrosis are currently Incyte/Novartis’ Jakafi (ruxolitinib), a $1.4bn JAK 1/2 inhibitor first approved in 2011, and Celgene’s newer JAK inhibitor  Inrebic ... Some analysts think Inrebic could become a

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    Currently in the middle of merger. After a turbulent development, Celgene has finally claimed FDA approval for Inrebic, its new drug for rare bone marrow disorder myelofibrosis. ... Inrebic (fedratinib) is the second JAK inhibitor to be approved for

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....
The power of communication: Engaging diverse groups in healthcare
Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....